Submit

Login Login

Register Register

Home / Journals / OR / Online First / doi:10.32604/or.2024.049348
Journal Menu
Special Issues
Table of Content

All issues

Online First

2024

2023

2022

2021

2020

2019

2018

2017

2016

Past Issues

Open Access

ARTICLE

Unveiling the therapeutic potential: KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activation in vitro

JINXIA CHEN1,2,3,#, SULI DAI1,2,#, GENG ZHANG4,5, SISI WEI1,2, XUETAO ZHAO3, YANG ZHENG1,2, YAOJIE WANG1,2, XIAOHAN WANG1,2, YUNJIANG LIU4,5,*, LIANMEI ZHAO1,2,*
1 Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China
2 Key Laboratory of Tumor Gene Diagnosis, Prevention and Therapy, Clinical Oncology Research Center, Shijiazhuang, 050000, China
3 Department of Blood Transfusion, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China
4 Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China
5 Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Hebei Medical University, Shijiazhuang, 050000, China
* Corresponding Author: YUNJIANG LIU. Email: email; LIANMEI ZHAO. Email: email
(This article belongs to the Special Issue: Recent Advances in Cancer Pharmacology)

Oncology Research https://doi.org/10.32604/or.2024.049348

Received 04 January 2024; Accepted 25 March 2024; Published online 29 May 2024

Abstract

Background: Triple-negative breast cancer (TNBC) is a heterogeneous, recurring cancer characterized by a high rate of metastasis, poor prognosis, and lack of efficient therapies. KBU2046, a small molecule inhibitor, can inhibit cell motility in malignant tumors, including breast cancer. However, the specific targets and the corresponding mechanism of its function remain unclear. Methods: In this study, we employed (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium) (MTS) assay and transwell assay to investigate the impact of KBU2046 on the proliferation and migration of TNBC cells in vitro. RNA-Seq was used to explore the targets of KBU2046 that inhibit the motility of TNBC. Finally, confirmed the predicted important signaling pathways through RT-qPCR and western blotting. Results: In this study, we found that KBU2046 functioned as a novel transforming growth factor-β (TGF-β1) inhibitor, effectively suppressing tumor cell motility in vitro. Mechanistically, it directly down-regulated leucine-rich repeat-containing 8 family, member E (LRRC8E), latent TGFβ-binding protein 3 (LTBP3), dynein light chain 1 (DNAL1), and MAF family of bZIP transcription factors (MAFF) genes, along with reduced protein expression of the integrin family. Additionally, KBU2046 decreased phosphorylation levels of Raf and ERK. This deactivation of the ERK signaling pathway impeded cancer invasion and metastasis. Conclusions: In summary, these findings advocate for the utilization of TGF-β1 as a diagnostic and prognostic biomarker and as a therapeutic target in TNBC. Furthermore, our data underscore the potential of KBU2046 as a novel therapeutic strategy for combating cancer metastasis.

Graphical Abstract

Unveiling the therapeutic potential: KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activation <i>in vitro</i>

Keywords

KBU2046; TGF-β1 (transforming growth factor-β1); LRRC (leucine-rich repeat-containing); LTBP (leucine-rich repeat-containing); Breast cancer (BC); Integrin αv; Integrin α6

  • 237

    View

  • 36

    Download

  • 0

    Like

Related articles
Copyright© 2024 Tech Science Press
© 1997-2024 TSP (Henderson, USA) unless otherwise stated

Share Link